MannKind Corporation (MNKD): What’s the Latest: New Insulin Inhaler, Rating Reiterated by Zacks, Matthew J. Pfeffer & More

Editor’s Note: MannKind Corporation (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Merck & Co., Inc. (NYSE:MRK)

For Diabetics, a New Insulin Inhaler Could Replace Shots as Early as 2014 (Businessweek)
The long promise of insulin that diabetics can inhale appears to be moving closer to the market. An inhalable insulin powder called Afrezza showed positive results for controlling diabetes in a late-stage clinical trial, the drug’s maker, MannKind Corporation (NASDAQ:MNKD), reported today. Pharmaceutical companies have been working on inhalable insulin for a long time on the theory that diabetics would prefer to puff on an inhaler than give themselves a shot. In 2007, Pfizer (PFE) stopped selling its Exubera insulin powder because of weak sales after less than two years on the market. Exubera never gained traction, largely because insurers wouldn’t pay for it, saying it was too expensive and didn’t work for many patients. Eli Lilly & Co. (LLY) and Novo Nordisk (NVO) both ended inhaled insulin research programs in 2008.

MannKind Corporation (NASDAQ:MNKD)MannKind Corp. Rating Reiterated by Zacks (MNKD) (Watch List News)
MannKind Corporation (NASDAQ:MNKD)‘s stock had its “neutral” rating reaffirmed by Zacks in a research report issued to clients and investors on Wednesday, AR Network reports. They currently have a $7.25 target price on the stock. Zacks‘ price objective points to a potential upside of 5.69% from the stock’s previous close. Zacks‘ analyst wrote, “MannKind’s second quarter 2013 net loss of $0.16 per share was narrower than the year-ago loss of $0.23 but wider than the Zacks Consensus Estimate of a loss of $0.15. We expect investor focus to remain on Afrezza.

Investors Purchase High Volume of MannKind Corp. Put Options (MNKD) (Watch List News)
Shares of MannKind Corporation (NASDAQ:MNKD) was the recipient of unusually large options trading activity on Monday. Traders acquired 11,596 put options on the company, Stock Ratings Network reports.This is an increase of approximately 114% compared to the average volume of 5,418 put options. In other MannKind Corp. news, CFO Matthew J. Pfeffer sold 10,000 shares of MannKind Corp. stock in a transaction that occured on Thursday, August 1st. The stock was sold at an average price of $8.00, for a total transaction of $80,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission.

Healthcare Stocks in Spotlight – MannKind Corporation (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Merck & Co., Inc. (NYSE:MRK) (Techsonian)
King Penny Stocks is an elite financial community for investors and traders alike who are looking to potentially gain financial freedom through the markets on undervalued companies and “in-play” momentum penny stocks. Today We bring special trend analysis of following stocks: MannKind Corporation (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Merck & Co., Inc. (NYSE:MRK). MannKind Corporation reported the gain of +17.93% to $8.09 in the mid-day trading session with the total traded volume of 31.37 million shares more than the average volume of 6.37 million. MNKD has market cap of 2.45 billion and its beta value stands at 1.41 times. MannKind Corporation (MannKind) is a development-stage biopharmaceutical company.

MannKind Diabetes Drug Tops Expectations in Study, Shares Soar (Fox Business)
Shares of MannKind Corporation (NASDAQ:MNKD) climbed 20% Wednesday morning after the company revealed positive late-stage trial results for its experimental diabetes drug. The Valencia, Calif.-based drug developer said two Phase III clinical studies for Afrezza, an ultra rapid-acting mealtime insulin therapy administered through MannKind’s next-generation inhaler, met their primary endpoints. The results “will form the basis of an amendment to our new drug application for AFREZZA, which we expect to submit to the Food and Drug Administration early in the fourth quarter of this year,” MannKind CEO Alfred Mann said in a statement.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Rito Pls Buff: The 10 Least Played Champions in LoL Season 4

10 Covers of Popular Songs that are Better than the Originals

Must See TV: The 9 Most Anticipated Shows of 2015

The 15 Biggest Box Office Bombs of All Time

10 Things The World Can’t Stand About Americans

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Burger Kings: The 10 Most Expensive Burgers in the World

The 10 Most Ethnically Diverse Countries in the World

The 10 Most Exclusive Credit Cards in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!